App-Quantinova.ai

OUTCOMES OF COVID-19 INFECTION AMONG CHILDREN AND YOUNG PEOPLE WITH PRE-EXISTING RHEUMATIC AND MUSCULOSKELETAL DISEASES

L. Kearsley-Fleet - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

OVERLAPPING FEATURES OF RELAPSING POLYCHONDRITIS AND SWEET’S SYNDROME: COULD THIS BE VEXAS (VACUOLES, UBIQUITIN A1E MUTATION, X-LINKED, AUTOINFLAMMATORY, SOMATIC) SYNDROME?

A. Vivekanantham - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Relapsing polychondritis

Methotrexate

PATHOPHYSIOLOGY OF ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION: A SYSTEMATIC LITERATURE REVIEW TO INFORM EULAR POINTS TO CONSIDER

A. Najm - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

PATIENT CHARACTERISTICS & CLINICAL FEATURES ASSOCIATE WITH HEALTH-RELATED QUALITY OF LIFE IN BIO-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH WEEK 24 OF THE DISCOVER-2 STUDY

J. Curtis - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Psoriatic arthritis

guselkumab (IV)

PATIENT JOURNEY WITH AXIAL SPONDYLOARTHRITIS: CRITICAL ISSUES FROM THE PATIENT PERSPECTIVE. RESULTS FROM THE EUROPEAN MAP OF AXIAL SPONDYLOARTHRITIS (EMAS)

M. Garrido-Cumbrera - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

PATIENT PREFERENCES, TRADE-OFFS AND ACCEPTABLE RISKS IN THE TREATMENT OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A STEP TOWARDS SHARED DECISION-MAKING

C. Bruni - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Interstitial lung disease

N/A

PERCEIVED SATISFACTION WITH CHRONIC PAIN CARE IN GERMAN PATIENTS WITH FIBROMYALGIA (FM)

M. Offenb�cher - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Fibromyalgia

N/A

PERFORMANCE OF PATIENT REPORTED OUTCOMES (PROs) IN SCLERODERMA PATIENTS WITH REDUCED LUNG FUNCTION IN AN OBSERVATIONAL COHORT

M. G. Lazzaroni - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Nintedanib

PERFUSE: A FRENCH PROSPECTIVE/RETROSPECTIVE NONINTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; 12-MONTH ANALYSIS

B. Fautrel - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Axial spondyloarthritis

Infliximab Biosimilar

PHARMACOVIGILANCE PREGNANCY DATA IN A LARGE POPULATION OF PATIENTS WITH CHRONIC INFLAMMATORY DISEASE EXPOSED TO CERTOLIZUMAB PEGOL: PREGNANCY OUTCOMES AND CONFOUNDERS

M. Clowse - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Certolizumab pegol

PHASE 3 TRIAL OF LENABASUM, A CB2 AGONIST, FOR THE TREATMENT OF DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC)

R. Spiera - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Scleroderma

Ajulemic acid

PHYSICAL FUNCTION IN PATIENTS WITH RA, STRATIFIED BY SEROSTATUS AND TREATMENT LINE, FOLLOWING SC ABATACEPT: POST HOC ANALYSIS OF AN OBSERVATIONAL, 2-YEAR STUDY CONDUCTED IN ROUTINE CLINICAL PRACTICE (ASCORE)

R. Alten - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Abatacept

PHYSICIAN AND PATIENT ATTITUDES TOWARDS TREAT-TO-TARGET, ITS IMPLEMENTATION AND STATED TREATMENT GOALS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A REAL-WORLD SETTING ACROSS EUROPE

B. Fautrel - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

PHYSICIAN AND PATIENT PERCEPTIONS OF SURGICAL PROCEDURES FOR KNEE OA ACROSS JAPAN, THE US AND 5 EU COUNTRIES: RESULTS OF A REAL-WORLD STUDY

N. Fukui - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

PLASMA MICROVESICLES AS LIQUID BIOPSIES OF THE ARTERIAL WALL IN LARGE VESSEL VASCULITIS

E. Tombetti - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Large vessel vasculitis

Becaplermin

POOLED SAFETY RESULTS FROM TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH 1 YEAR

C. T. Ritchlin - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

guselkumab (IV)

POST-TRIAL SURVEY OF PARTICIPANTS OF A PHASE 3 CLINICAL TRIAL IN SSC-ILD

I. Galetti - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Nintedanib

PREDICTORS OF HOSPITALISATION IN PATIENTS WITH RHEUMATIC DISEASE AND COVID-19 IN IRELAND: DATA FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRY

R. Conway - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

PREDICTORS OF PSORIATIC ARTHRITIS DEVELOPMENT IN PSORIASIS PATIENTS: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS

A. Zabotti - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

N/A

PREDICTORS OF TOXICITY WITH HYDROXYCHLOROQUINE AND CHLOROQUINE USE: A SYSTEMATIC REVIEW

N. Citeroni - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Hydroxychloroquine

Filters

45280 Abstracts